TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1408301

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (5%)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Isotonic saline (0.9%)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Experimental pain
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pain from memory
Number of subjects: 31

Group type: COMPARATOR
Intervention: Baseline recordings
Number of subjects: 31
Study: 2866607

Group type: EXPERIMENTAL
Intervention: Acetylcysteine 200 mg three times a day
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 10872406

Group type: EXPERIMENTAL
Intervention: Chemomechanical caries removal system (CRS)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional caries removal (control)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both CRS and control procedures
Number of subjects: 47
Study: 31175436

Group type: EXPERIMENTAL
Intervention: Guided Self‐Determination Gynecological Cancer (GSD‐GYN‐C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 30225985

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) injections (100 or 30 units)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 50
Study: 28271453

Group type: EXPERIMENTAL
Intervention: Food-specific inhibition training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control condition (free exploration of food pictures)
Number of subjects: 22
Study: 26298674

Group type: EXPERIMENTAL
Intervention: Universal preventative intervention including a student social relationship/emotional health curriculum and parent/caregiver parenting education
Number of subjects: 2027

Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 2027
Study: 23457222

Group type: EXPERIMENTAL
Intervention: Gravitational shunt valves
Number of subjects: 145

Group type: COMPARATOR
Intervention: Programmable valves (Control)
Number of subjects: 145
Study: 21091365

Group type: EXPERIMENTAL
Intervention: Xuezhikang
Number of subjects: 2704

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2704
Study: 18596714

Group type: EXPERIMENTAL
Intervention: Home visits by trained community health workers (CHWs) within 3 days of birth
Number of subjects: 3495

Group type: COMPARATOR
Intervention: No home visit by CHWs
Number of subjects: 3495
Study: 16990384

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow-derived progenitor cells (BMC)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo medium
Number of subjects: 204
Study: 15107600

Group type: EXPERIMENTAL
Intervention: Levosimendan (LS) 0.5 mg four times daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Levosimendan (LS) 0.5 mg four times daily with felodipine (FD) 5 mg once daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Felodipine (FD) 5 mg once daily
Number of subjects: 24
Study: 11048468

Group type: COMPARATOR
Intervention: Epsilon-aminocaproic acid (EACA)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 48
Study: 8838439

Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride (150 mg twice daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ethanol (0.15 g kg-1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ethanol (0.3 g kg-1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ethanol (0.6 g kg-1)
Number of subjects: 24
Study: 1595589

Group type: EXPERIMENTAL
Intervention: Chronic magnesium administration (CMA) 4.5 g/d for 4 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 12
Study: 6375411

Group type: EXPERIMENTAL
Intervention: Penile block with 0.5 percent bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: No nerve block
Number of subjects: 0
Study: 31477748

Group type: EXPERIMENTAL
Intervention: Preservative-free diquafosol administered 6 times daily after surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preservative-containing diquafosol administered 6 times daily after surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preservative-free hyaluronate administered 6 times daily after surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preservative-free diquafosol
Number of subjects: 0
Study: 29504880

Group type: EXPERIMENTAL
Intervention: Acetaminophen/Codeine (Tylex 30 mg: acetaminophen 500 mg/codeine 30 mg)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Acetaminophen/Codeine (Tylex)
Number of subjects: 105
Study: 26420678

Group type: EXPERIMENTAL
Intervention: Calcium-based phosphate binder + Nicotinamide (100 mg twice or three times daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Calcium-based phosphate binder
Number of subjects: 60
Study: 25089860

Group type: EXPERIMENTAL
Intervention: 40-mg triamcinolone acetonide subacromial corticosteroid injection (CSI)
Number of subjects: 104

Group type: COMPARATOR
Intervention: 6 sessions of manual physical therapy
Number of subjects: 104
Study: 22471392

Group type: EXPERIMENTAL
Intervention: Atenolol 75 mg for 4 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg for 4 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg for 4 weeks
Number of subjects: 18
Study: 20733968

Group type: EXPERIMENTAL
Intervention: Algorithmic approach to management of lumbar spinal stenosis
Number of subjects: 1
Study: 17931342

Group type: EXPERIMENTAL
Intervention: Capsaicin (0.75 mg)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 115
Study: 15667242

Group type: EXPERIMENTAL
Intervention: Benchmarking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benchmarking dataset
Number of subjects: 0
Study: 11929327

Group type: EXPERIMENTAL
Intervention: Spironolactone (aldosterone antagonist) added to existing therapy
Number of subjects: 0
Study: 11289497

Group type: EXPERIMENTAL
Intervention: Acute myocardial infarction (AMI)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Stable angina pectoris (AP)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Old myocardial infarction (OMI)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (atypical chest pain)
Number of subjects: 76
Study: 9011455

Group type: EXPERIMENTAL
Intervention: Somatostatin (250 microg bolus injection)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1431691

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser applied to the apical surface of resected roots
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonlased roots
Number of subjects: 60
Study: 3859595

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 200 mg
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 100 mg
Number of subjects: 205

Group type: COMPARATOR
Intervention: Buffered aspirin
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 31557429

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Number of subjects: 1495

Group type: COMPARATOR
Intervention: Hemiarthroplasty
Number of subjects: 1495
Study: 29800468

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for insomnia (CBT-I)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for insomnia plus positive mood strategies (CBT-I+)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Psychoeducation control group (PCG)
Number of subjects: 72
Study: 27390111

Group type: EXPERIMENTAL
Intervention: Real attentional bias training (ABT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham attentional bias training (ABT)
Number of subjects: 41
Study: 25706772

Group type: EXPERIMENTAL
Intervention: Nigella sativa (NS) 2g daily for one year
Number of subjects: 114

Group type: COMPARATOR
Intervention: Activated charcoal (placebo)
Number of subjects: 114
Study: 23414791

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-TnI)
Number of subjects: 3623

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-TnT)
Number of subjects: 3623
Study: 20026488

Group type: EXPERIMENTAL
Intervention: Hyaluronan-based heparin-bonded circuits (Vision HFO-GBS, Gish, CA, USA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Uncoated controls
Number of subjects: 90
Study: 18558796

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 16583

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16583
Study: 15681624

Group type: EXPERIMENTAL
Intervention: Testosterone gel 1% (5 g applied once a day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12854797

Group type: EXPERIMENTAL
Intervention: Mandibular overdentures retained by two implants
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional mandibular complete dentures
Number of subjects: 60
Study: 10435208

Group type: EXPERIMENTAL
Intervention: Naloxone 0.1 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naloxone 2.0 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naloxone 0.5 mcg/kg (test dose)
Number of subjects: 20
Study: 8627976

Group type: EXPERIMENTAL
Intervention: Intracoronary nicorandil (0.25, 0.50, 1.0 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN; 1.0 mg)
Number of subjects: 46
Study: 2077525

Group type: EXPERIMENTAL
Intervention: Oxycodone (intravenous)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxycodone (oral)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Morphine (intravenous)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Morphine (oral)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Morphine glucuronides
Number of subjects: 10
Study: 6793182

Group type: EXPERIMENTAL
Intervention: Chlorpropamide (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpropamide (two weeks treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpropamide (single tablet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma chlorpropamide or alcohol concentrations
Number of subjects: 0
Study: 31055958

Group type: EXPERIMENTAL
Intervention: Fosmetpantotenate
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 27986648

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 253
Study: 26656357

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 63
Study: 23398127

Group type: EXPERIMENTAL
Intervention: Citalopram treatment in premenopausal women taking hormonal contraceptives
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Citalopram treatment in postmenopausal women taking hormone therapy
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Citalopram treatment in premenopausal women not taking contraception/HT
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Citalopram treatment in postmenopausal women not taking contraception/HT
Number of subjects: 1440
Study: 21385354

Group type: EXPERIMENTAL
Intervention: 1% tenofovir gel
Number of subjects: 889
Study: 19811373

Group type: EXPERIMENTAL
Intervention: Augmentation therapy with exogenous α1-antitrypsin (α1-AT)
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Control regimen (not specified)
Number of subjects: 1509
Study: 17066085

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg + Indapamide 1.25 mg
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo (substituted for Perindopril 4 mg + Indapamide 1.25 mg)
Number of subjects: 135
Study: 14742402

Group type: EXPERIMENTAL
Intervention: Preoperative autologous donation (PAD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cell salvage (CS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both PAD and CS
Number of subjects: 50
Study: 11176201

Group type: EXPERIMENTAL
Intervention: Soluble fiber intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-saturated fat diet with fiber sources
Number of subjects: 0
Study: 9781918

Group type: EXPERIMENTAL
Intervention: Zatebradine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 8080674

Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 102

Group type: COMPARATOR
Intervention: Metoclopramide plus lorazepam
Number of subjects: 102
Study: 2806927

Group type: EXPERIMENTAL
Intervention: levodopa administration
Number of subjects: 16

Group type: COMPARATOR
Intervention: control experiments without levodopa administration
Number of subjects: 16
Study: 335382

Group type: EXPERIMENTAL
Intervention: Nerisone cream (diflucortolone valerate 0.1%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluocinolone-acetonide ointments
Number of subjects: 30
Study: 30273002

Group type: EXPERIMENTAL
Intervention: Videogame intervention (Crazy Taxi), 60 sessions of 1 hour each over 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computerized training program (PositScience InSight), 60 sessions of 1 hour each over 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training (usual care/no intervention)
Number of subjects: 0
Study: 27861239

Group type: EXPERIMENTAL
Intervention: Community + individual interventions (Arm 4)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Standard of care (Arm 1)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Community intervention alone (Arm 2)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Individual intervention alone (Arm 3)
Number of subjects: 455
Study: 25452629

Group type: EXPERIMENTAL
Intervention: Removable vacuum‐formed retainer (VFR) covering the palate and the maxillary anterior teeth from canine‐to‐canine and bonded canine‐to‐canine retainer in the lower arch (group V‐CTC)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Maxillary VFR combined with stripping of the lower anterior teeth (group V‐S)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Prefabricated positioner (group P)
Number of subjects: 49
Study: 23867047

Group type: EXPERIMENTAL
Intervention: DEVS programme (intervention group)
Number of subjects: 1752

Group type: COMPARATOR
Intervention: Control group (usual drug education)
Number of subjects: 1752
Study: 22475112

Group type: COMPARATOR
Intervention: Placebo arm
Number of subjects: 1778

Group type: EXPERIMENTAL
Intervention: Blind trial
Number of subjects: 1778
Study: 19265605

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both RCTs and observational studies
Number of subjects: 0
Study: 17485709

Group type: EXPERIMENTAL
Intervention: Periareolar injection of radiotracer and blue dye
Number of subjects: 449

Group type: COMPARATOR
Intervention: Peritumoral injection of radiotracer and blue dye
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Periareolar injection of blue dye and/or gamma probe
Number of subjects: 449

Group type: COMPARATOR
Intervention: Peritumoral injection of blue dye and/or gamma probe
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Periareolar injection of blue dye
Number of subjects: 449

Group type: COMPARATOR
Intervention: Peritumoral injection of blue dye
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Periareolar injection by probe
Number of subjects: 449

Group type: COMPARATOR
Intervention: Peritumoral injection by probe
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Periareolar injection
Number of subjects: 449

Group type: COMPARATOR
Intervention: Peritumoral injection
Number of subjects: 449
Study: 15189916

Group type: EXPERIMENTAL
Intervention: Influenza vaccination (purified, trivalent, split-virus vaccine)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 125
Study: 15704358

Group type: EXPERIMENTAL
Intervention: Ceftibuten (9 mg/kg, once daily for 5 days)
Number of subjects: 2099

Group type: COMPARATOR
Intervention: Penicillin V (50,000 IU/kg, divided in three doses for 10 days)
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Ceftibuten
Number of subjects: 2099

Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Ceftibuten and Penicillin V
Number of subjects: 2099
Study: 9826222

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes mellitus (IDDM) subjects
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes mellitus (IDDM) subjects with normoalbuminuria
Number of subjects: 130
Study: 7985162

Group type: EXPERIMENTAL
Intervention: Capoten treatment according to the chronosensitivity-adjusted regimen
Number of subjects: 29

Group type: COMPARATOR
Intervention: Capoten treatment according to the conventional scheme
Number of subjects: 29
Study: 2605079

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Alfentanil 0.5 mg
Number of subjects: 20
Study: 30911271

Group type: EXPERIMENTAL
Intervention: Single-dose dexmedetomidine (0.5 μg/kg) combined with low-dose remifentanil infusion (1 ng/mL)
Number of subjects: 169

Group type: COMPARATOR
Intervention: High-dose remifentanil infusion (2 ng/mL)
Number of subjects: 169
Study: 29122953

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD; 1250 kcal/day) for 12 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Very-low-calorie diet (VLCD; 500 kcal/day) for 5 weeks followed by a weight stable period of 4 weeks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Changes in ACE activity during dietary intervention
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Changes in FFA concentrations during dietary intervention
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Changes in RBP4 concentrations during dietary intervention
Number of subjects: 56
Study: 25387342

Group type: EXPERIMENTAL
Intervention: Phacoemulsification and goniosynechialysis (PEGS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phacoemulsification alone (PE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of PEGS and PE
Number of subjects: 30
Study: 23978169

Group type: EXPERIMENTAL
Intervention: Modular treatment (MATCH)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 174
Study: 21178605

Group type: EXPERIMENTAL
Intervention: Preemptive low-dose epidural ketamine (0.12% levobupivacaine, 2 μg/mL of fentanyl, 0.2 mg/mL ketamine, total volume of 500 mL)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Preemptive thoracic epidural analgesia without ketamine (0.12% levobupivacaine, 2 μg/mL of fentanyl, total volume of 500 mL)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Preemptive low-dose epidural ketamine
Number of subjects: 133

Group type: COMPARATOR
Intervention: Preemptive thoracic epidural analgesia without ketamine
Number of subjects: 133
Study: 18155054

Group type: EXPERIMENTAL
Intervention: EMLA cream (lidocaine 2.5% and prilocaine 2.5%), approximately 5 g
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (neomycin ointment, approximately 5 g)
Number of subjects: 30
Study: 16926693

Group type: EXPERIMENTAL
Intervention: Case management model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 12603175

Group type: EXPERIMENTAL
Intervention: Diclofenac (75mg twice daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Celecoxib (200mg twice daily)
Number of subjects: 24
Study: 11137591

Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed at discharge (amoxicillin clavulanate in 41%, amoxicillin in 15%, cefuroxime axetil in 11%, cefaclor 6%, azithromycin 5%)
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: First choice antibiotics
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Alternate use antibiotics
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Inadequate treatment
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Variability in antibiotic prescription
Number of subjects: 821
Study: 9205758

Group type: EXPERIMENTAL
Intervention: Ebrotidine single doses (25 to 1600 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ebrotidine multiple doses (400 to 800 mg every 12 hours for 12 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ebrotidine (single and multiple doses)
Number of subjects: 16
Study: 7810458

Group type: EXPERIMENTAL
Intervention: Mainstreamed students
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other program placements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional-behavioral functioning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite score of the emotional-behavioral scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Level of functioning
Number of subjects: 0
Study: 3076709

Group type: EXPERIMENTAL
Intervention: Mefloquine-sulfadoxine-pyrimethamine (MSP) at doses of 1, 1.5, or 2 standard MSP tablets (equivalent to 7.1-12.5 mg/kg mefloquine, 14.3-25.0 mg/kg sulfadoxine, 0.7-1.3 mg/kg pyrimethamine)
Number of subjects: 60
Study: 30989073

Group type: EXPERIMENTAL
Intervention: Cold diet
Number of subjects: 120
Study: 28088798

Group type: EXPERIMENTAL
Intervention: Intracranial‐B2LEED3S score derived from PERFORM trial
Number of subjects: 39432

Group type: EXPERIMENTAL
Intervention: Low-risk patients (score ≤2)
Number of subjects: 39432

Group type: EXPERIMENTAL
Intervention: High-risk patients (score ≥5)
Number of subjects: 39432

Group type: EXPERIMENTAL
Intervention: PERFORM trial
Number of subjects: 39432

Group type: EXPERIMENTAL
Intervention: PRoFESS trial
Number of subjects: 39432
Study: 25794622

Group type: EXPERIMENTAL
Intervention: TSHH (7.5 μg tiotropium/25 μg salmeterol, once daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: TioHH (18 μg tiotropium, once daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: SalD (50 μg salmeterol, twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Combination of TioHH (qd) plus SalD (bid)
Number of subjects: 50